The patent maze of COVID 19 vaccines

References

• Young ML, Dickstein B, Weibel RE, et al. “Experiences with Jeryl Lynn strain live attenuated mumps virus vaccine in a pediatric outpatient clinic„. Pediatrics. American Academy of Pediatrics. 1967;40(5):798–803.
   PubMed Web of Science ®Google Scholar
• Wolf J, Bruno S, Eichberg M, et al. Applying lessons from the Ebola vaccine experience for SARS-CoV-2 and other epidemic pathogens. Npj Vaccines. 2020;5(1):51.
   PubMed Web of Science ®Google Scholar
• [cited 2021 Mar 15]. Available from: https://msfaccess.org/india-and-south-africa-proposal-wto-waiver-ip-protections-covid-19-related-medical-technologies
   Google Scholar
• Martin C, Lowery D. mRNA vaccines: intellectual property landscape. Nat Rev Drug Discov. 2020;19(9):578.
   Web of Science ®Google Scholar
• [cited 2021 Mar 15]. Available from: https://blog.jonasneubert.com/2021/01/10/exploring-the-supply-chain-of-the-pfizer-biontech-and-moderna-covid-19-vaccines/#fn:4
   Google Scholar
• Heidt A. Self-Experimentation in the Time of COVID-19. Scientist. 2020 Aug.
   Google Scholar
• [cited 2021 Mar 15]. Available from: https://radvac.org/white-paper/
   Google Scholar
• Hoerr I, Obst R, Rammensee HG, et al. In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. Eur J Immunol. 2000 Jan;30(1):1–7.
   PubMed Web of Science ®Google Scholar
• Yaworski et al.; Protiva/Arbutus; Non-liposomal systems for nucleic acid delivery (US9404127B2; Priority date: 30.06.2010); Yaworski et al; Protiva/Arbutus; Lipid formulations for nucleic acid delivery (US9364435B2; Priority date: 15. 04.2008);Yaworski et al; Protiva/Arbutus; Lipid formulations for nucleic acid delivery (US8058069B2; Priority date: 15. April.2008)
   Google Scholar
• Sahin et al., inventors, Biontech, assignee. Formulation for administration of rna (US2019321458A1; Priority date: 15.July.2016)
   Google Scholar
• Karikó K, Muramatsu H, Fa W, et al., Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther. 2008;16(11):1833–1840.
   PubMed Web of Science ®Google Scholar
• Kariko et al.; inventors, University of Pennsylvania; Rna containing modified nucleosides and methods of use thereof (US8278036B2; Priority date: 23. August.2005)
   Google Scholar
• De Fougerolles et al.; inventors, ModernaTX; Modified nucleosides, nucleotides, and nucleic acids, and uses thereof (US9428535B2; Priority date: 03.October.2011)
   Google Scholar
• Thess A, Grund S, Mui BL, et al. Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals. Mol Ther. 2015;23(9):1456–1464.
   PubMed Web of Science ®Google Scholar
• Von der Mülbe et al.; inventors, Curevac; Pharmaceutical composition containing a stabilised mrna which is optimised for translation in the coding regions thereof (EP1392341B1; Priority date: 05.June.2001)
   Google Scholar
• Ciaramella et al.; ModernaTX; Betacoronavirus mrna vaccine (US10702600B1; Priority date: 22.October.2015)
   Google Scholar
• Ciaramella et al, inventors, ModernaTX, assignee. Betacoronavirus mRNA vaccine. United States patent (US10933127B2. Priority date: 22. 10. 2015).
   Google Scholar
• Kallen et al.; inventors, Curevac; Vaccination with mRNA-coded antigens (US2021023199A1; Priority date: 02.March.2011)
   Google Scholar
• Kallen et al.; inventors, Curevac; Vaccination in elderly patients (WO2012116811A1; Priority date: 02.March.2011)
   Google Scholar
• Fotin-Mleczek et al.; inventors, Curevac; Methods of immunostimulation with complexes of rna and cationic carriers (US2021060175A1; Priority date: 04.Sep.2007)
   Google Scholar
• Fotin-Mleczek et al.; inventors, Curevac; Complexes of rna and cationic peptides for transfection and for immunostimulation (WO2009030254A1; Priority date: 04.Sep.2007)
   Google Scholar
• Hefesha et al.; inventors, Biontech; Lipid particle formulations for delivery of rna and water-soluble therapeutically effective compounds to a target cell (EP3277263A1; Priority date: 31.March.2015)
   Google Scholar
• Haas et al.; inventors, Biontech; Preparation and storage of liposomal rna formulations suitable for therapy (WO2020201383A1; Priority date: 05.April.2019)
   Google Scholar
• Hoffman et al.; inventors, Pfizer; Anticoronviral compounds and compositions, their pharmaceutical uses and materials for their synthesis (WO2005113580A1; Priority date: 21.May.2004)
   Google Scholar
• Gill et al.; inventors, Pfizer; Canine coronavirus vaccine. (EP0295057A2; Priority date: 08.July.1987)
   Google Scholar
• Miller et al.; inventors, Pfizer; Compositions and methods for vaccination against coronaviruses. (EP0640097A4; Priority date: 08.May.1992)
   Google Scholar
• [cited 2021 Mar 15]. Available from: https://investors.modernatx.com/news-releases/news-release-details/statement-moderna-intellectual-property-matters-during-covid-19
   Google Scholar
• Luitjens et al.; inventors, Janssen; Method for the production of ad26 adenoviral vectors (EP2536829B1; Priority date: 15.Feb.2010)
   Google Scholar
• Dicks et al.; inventors, Oxford University; Simian adenovirus and hybrid adenoviral vectors (EP2714916B1; Priority date: 25.May.2011)
   Google Scholar
• Oxford University; (GB202016604(unpublished application); Priority date: 20.October.2020)
   Google Scholar
• Zubkova et al.; inventors, Gamaleya Institute; Immunobiological agent and a method for use thereof for inducing specific immunity against the sars-cov-2 severe acute respiratory syndrome virus (RU2720614C9; Priority date: 23. April.2020)
   Google Scholar
• Zubkova et al.; inventors, Gamaleya Insittute; Immunobiological agent for inducing specific immunity against severe acute respiratory syndrome virus sars-cov-2 (WO2021002776A1; Priority date: 23. April.2020)
   Google Scholar
• Morein et al.; inventors, Novavax; Quil a fraction with low toxicity and use thereof (US8821881B2; Priority date: 07. July 2003)
   Google Scholar
• Robinson et al.; inventors, Novavax; Insect cell line (US7041500B2; Priority date: 14. Feb.2002)
   Google Scholar
• Kost T, Condreay J, Jarvis D. Baculovirus as versatile vectors for protein expression in insect and mammalian cells. Nat Biotechnol. 2005;23(5):567–575.
   PubMed Web of Science ®Google Scholar
• Kensil et al.; inventors, Cambridge Biotech; Saponin adjuvant (US5057540A; Priority date: 29.May.1987)
   Google Scholar
• Campillo-Agusti et al; Inovio Pharmaceuticals; Electroporation device with detachable needle array with lock-out system (EP3397337B1; Priority date: 30.Dec.2015)
   Google Scholar
• Weiner et al; Inovio Pharmaceuticals; Mers-CoV vaccine (US10548971B2; Priority date: 29.November.2013)
   Google Scholar
• Hebel et al.; inventors, Advisys; Devices and methods for biomaterial production (US7238522B2; Priority date: 30.may.2003)
   Google Scholar
• [cited 2021 Mar 15]. Available from: https://www.cbsnews.com/news/coronavirus-vaccine-san-diego-lab-inovio-pharmaceuticals-discovered-drug-testing/
   Google Scholar
• Hammond E, TWN Series on Intellectual Property and COVID-19 Vaccines, June 2020
   Google Scholar
• Cai Y, Zhang J, Xiao T, et al. Distinct conformational states of SARS-CoV-2 spike protein. Science. 2020Jul21;369(6511):1586–1592.
   Web of Science ®Google Scholar
• Cross R. The tiny tweak behind COVID-19 vaccines. Chem Eng News. 2020;98(38).
   Google Scholar
• Hsieh CL. Structure-based design of prefusion-stabilized SARS-CoV-2 spikes; Science. 2020;369(6510):1501-1505.
   Google Scholar
• Graham et al.; inventors, Dartmouth College et al; Prefusion coronavirus spike proteins and their use (US20200061185A1; Priority date: 25.October.2016)
   Google Scholar
• University of Texas; n/a (62/972,886(unpublished application); Priority date 11.February. 2020)
   Google Scholar
• Shaner et al. inventors, Allele Biotechnology; Novel Monomeric Yellow-Green Fluorescent Protein From Cephalochordate (US10221221B2; Priority date. 24.july.2012)
   Google Scholar